Dianthus Therapeutics Inc. (DNTH)
DNTH trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/0001690585-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DNTH on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001690585 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.0M |
| Net income | -$162.3M |
| Operating income | -$177.9M |
| Net margin | -7973.3% |
| Operating margin | -8739.3% |
| Revenue growth | -67.3% |
| Cash | $51.1M |
| Total assets | $530.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2476.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Liquidity In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying u" | 10-Q 2026-11-04 |
| Cash and burn | $55.7M cash; operating cash flow -$43.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 56,312,712 (2026-11-02); 42,876,015 a year earlier; 14,817,762 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-11 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Morristown, New Jersey, United States | PCAOB Form AP 2026-03-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $71.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$46.6M | -$50.3M | $55.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | Not filed | -$50.2M | -$49.0M | $110.5M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q1 2026 2026-03-31 | Not filed | -$40.8M | -$28.9M | $627.7M | No debt tags | Needs four quarters | 10-Q 2026-11-04 |
| Q4 2025 2025-12-31 | $284K | -$64.4M | -$47.0M | $51.1M | No debt tags | $2.0M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $396K | -$36.8M | -$30.6M | $56.0M | No debt tags | $3.1M | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | $193K | -$31.6M | -$23.9M | $13.2M | No debt tags | $4.9M | 10-Q 2025-08-07 |
| Q1 2025 2025-03-31 | $1.2M | -$29.5M | -$27.6M | $10.1M | No debt tags | $6.5M | 10-Q 2025-05-12 |
| Q4 2024 2024-12-31 | $1.3M | -$28.4M | -$27.4M | $22.8M | No debt tags | $6.2M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-09-18 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-09 |
Source: SEC EDGAR submissions feed, 661 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.7% |
| 1 month | +18.3% |
| 3 months | -16.2% |
| Year to date | +122.8% |
| 1 year | +158.6% |
| From 52-week high | -20.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LQDA | Liquidia Corporation | $56.37 | -1.81% | $5.1B |
| PTCT | PTC Therapeutics Inc. | $60.97 | -3.97% | $5.1B |
| ERAS | Erasca Inc. | $15.11 | -3.51% | $5.3B |
| EWTX | Edgewise Therapeutics Inc. | $43.68 | -4.90% | $4.8B |
| COGT | Cogent Biosciences Inc. | $27.44 | -3.92% | $4.8B |
| TVTX | Travere Therapeutics Inc. | $49.70 | -1.88% | $4.8B |
| MANE | Veradermics Incorporated | $128.05 | -1.24% | $5.4B |
| IONS | Ionis Pharmaceuticals Inc. | $28.01 | -3.61% | $4.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier